Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin and teicoplanin: something old, something new.

G Phillips1, C L Golledge

  • 1Department of Microbiology, Ninewells Hospital, Dundee, Scotland.

The Medical Journal of Australia
|January 6, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between weight concern, bullying, cigarette use, and vaping among heterosexual and sexual minority female adolescents.

Public health·2026
Same author

Dispositional moral attribution and association avoidance: explaining chronic mpox stigma even after recovery.

Ethics, medicine, and public health·2025
Same author

End-to-end SARS-CoV-2 transmission risks in sport: Current evidence and practical recommendations.

South African journal of sports medicine·2024
Same author

Contact load practices and perceptions in elite English rugby league: an evaluation to inform contact load guidelines.

South African journal of sports medicine·2024
Same author

The Burden Patients with Myasthenia Gravis Experience in Terms of Breathing, Fatigue, Sleep, Mental Health, Discomfort and Usual Activities in Comparison to the General Population.

Advances in therapy·2023
Same author

People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies.

Advances in therapy·2023
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

Vancomycin is the preferred glycopeptide antibiotic over teicoplanin due to superior activity against coagulase-negative staphylococci and established dosing. While teicoplanin has fewer side effects, vancomycin remains the top choice for Gram-positive bacterial infections.

Area of Science:

  • Pharmacology
  • Microbiology
  • Clinical Medicine

Background:

  • Glycopeptide antibiotics are crucial for treating Gram-positive bacterial infections.
  • Vancomycin and teicoplanin are key agents in this class.

Purpose of the Study:

  • To compare the pharmacology, in vitro activity, and clinical efficacy of vancomycin and teicoplanin.
  • To determine the optimal glycopeptide antibiotic for Gram-positive infections.

Main Methods:

  • Comprehensive literature search of MEDLINE, Index Medicus, textbooks, and product information.
  • Review of over 200 publications from Phase I trials onwards.
  • Critical analysis and synthesis of findings, addressing conflicting results.

Main Results:

Related Experiment Videos

  • Vancomycin demonstrates superior in vitro and in vivo activity against coagulase-negative staphylococci.
  • Reliable vancomycin dosage regimens are established.
  • Teicoplanin requires higher doses for maximal efficacy and has a marginal advantage in side effect profile.

Conclusions:

  • Vancomycin is the glycopeptide of choice for Gram-positive bacterial infections.
  • Differences in activity and dosing influence clinical utility.
  • Vancomycin offers a more established and effective treatment option.